Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial
Authors
Keywords
-
Journal
LANCET
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-05-16
DOI
10.1016/s0140-6736(21)01063-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis
- (2020) Mauro Chiarito et al. LANCET
- Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome
- (2020) Byeong-Keuk Kim et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial
- (2020) Hyo-Soo Kim et al. LANCET
- Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials
- (2020) Daniele Giacoppo et al. EUROPEAN HEART JOURNAL
- The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”
- (2018) Jeehoon Kang et al. Korean Circulation Journal
- 2018 ESC/EACTS Guidelines on myocardial revascularization
- (2018) Franz-Josef Neumann et al. EUROPEAN HEART JOURNAL
- Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
- (2018) J Michael Gaziano et al. LANCET
- Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly
- (2018) John J. McNeil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
- (2018) John J. McNeil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
- (2018) NEW ENGLAND JOURNAL OF MEDICINE
- 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
- (2017) Marco Valgimigli et al. EUROPEAN HEART JOURNAL
- Clopidogrel Use as Single Antiplatelet Therapy in Outpatients with Stable Coronary Artery Disease: Prevalence, Correlates and Association with Prognosis (from the CORONOR Study)
- (2016) Gilles Lemesle et al. CARDIOLOGY
- Clopidogrel Versus Aspirin as an Antiplatelet Monotherapy After 12-Month Dual-Antiplatelet Therapy in the Era of Drug-Eluting Stents
- (2016) Taek Kyu Park et al. Circulation-Cardiovascular Interventions
- Comparison of dual antiplatelet therapy prescribed as one-pill versus two-pill regimen
- (2016) Chang-Hwan Yoon et al. THROMBOSIS AND HAEMOSTASIS
- Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
- (2014) Laura Mauri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials
- (2012) Peter M Rothwell et al. LANCET
- AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update
- (2011) Sidney C. Smith et al. CIRCULATION
- Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials
- (2010) Peter M Rothwell et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started